Available in English, French and Spanish
The procurement of essential medicines and other health products is a critical function in support of the effective discharge of WHO’s mandate, and WHO values the importance of the quality of essential medicines and health products that are supplied to countries. The first World Health Assembly in... 1948 recognized the need to establish a procurement service at WHO, and recommended setting up an office “to give advice on the procurement of essential drugs, biological products and other medical supplies”.
more
In this subsequent part of the issue brief on the NTD Toolbox you will learn about general strategies, roadmaps, key
treatment guidelines, reports, and training material on Dengue & Chikungunya, Human African Trypanosomiasis and
Leprosy.
This training module is designed to equip health workers (HWs) with
knowledge, skills, confidence and resources to help them in their role to recommend the Human Papillomavirus
(HPV) vaccine.
WHO REPORT ON THE GLOBAL TOBACCO EPIDEMIC, 2017
This guidance note identifies strategic action for policy-makers and managers at the national, subnational and facility level to address these different challenges.
Pharmaceutical regulators are at the forefront of ensuring that only safe and effective medicines are authorized and available in the market. This document builds on the recommendations in the above publication and has been prepared to specifically assist national medicines regulatory authorities to... understand the nature and extent of oxytocin quality issues and to provide key technical information and quality requirements for oxytocin products in dossier assessments. Furthermore, this document also presents recommendations on other regulatory actions needed to ensure that only quality-assured oxytocin products are authorized and made available to women.
more
Le HCSP a fondé ses recommandations sur les connaissances actuellement disponibles en particulier les publications scientifiques relatives au COVID-19 mais aussi de recommandations relatives à la prise en charge des pneumonies post grippales, et des pneumonies sévères en réanimation.
Cet avi...s du HCSP délivre également des indications sur la prise en charge non spécifique, et de possibles thérapeutiques antivirales, dans l’attente de la mise en place d’essais thérapeutiques académiques afin de progresser dans la connaissance de la maladie. Ces recommandations relatives aux traitements spécifiques seront adaptées en fonction des résultats des essais cliniques lorsqu’ils seront disponibles.
more
As evidências atuais indicam que o vírus causador da doença COVID-19 é transmitido através de gotículas respiratórias ou por contato. A transmissão por contato ocorre quando as mãos contaminadas tocam a mucosa da boca, nariz ou olhos. O vírus também pode ser transferido de uma superfície... para outra através das mãos contaminadas, o que facilita a transmissão por contato indireto. Consequentemente, a higienização das mãos é extremamente importante para evitar a disseminação do vírus causador da doença COVID-19.
more
Цей документ описує кроки, необхідні для визначення скоригованого інтервалу QT (QTc) в
ході моніторингу ЕКГ пацієнтів, які отримують препарати для лікування ХР ТБ, що... викликають пролонгацію інтервалу QT. Він також надає рекомендації щодо ведення випадків пролонгації QTc.
more
There is an expanding market of no- and low-alcohol beverages (NoLos). However, their effects on global ethanol consumption and public health are still questioned. Policies and regulations about NoLos’ availability, acceptability and affordability are lacking and evidence about their benefits is l...imited. Concerns have been raised about the impact of NoLos in reducing alcohol consumption and its associated harm and the possible drawbacks and implications, such as misleading minors, pregnant women, abstainers or those seeking to stop drinking about their actual ethanol content. Further, there are concerns about the implications of NoLo branded products being displayed close to the brand’s main alcoholic beverages and their potential to subtly lead to new occasions of drinking. There is a need to monitor their consumption and impact on aggregated alcohol consumption to understand the public health implications of NoLos. The alcohol by volume content of NoLos must be defined, harmonised and clearly labelled. NoLo marketing needs to be regulated to protect children, pregnant women and those seeking to stop drinking. Fiscal and pricing policies to reduce the affordability of products with higher strengths of ethanol may favour a shift towards lower alcohol strength beverages.
more
INT J TUBERC LUNG DIS 22(2):197–205 http://dx.doi.org/10.5588/ijtld.17.0245
MMWR. Recommendations and Reports:
December 16, 2005 / 54(RR15);49-55